Programme

	Thursday 20 November - Day one
10.30am	Registration, welcome refreshments, exhibition and poster viewing
11.00am	Chair's welcome and introduction Dr Chris Dean, Lead Stereotactic Radiotherapy Physicist, Barts Health NHS Trust & Chair, UK SABR Consortium
11.05am	Specialised commissioning for Radiotherapy Dr Imogen Locke, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust
11.25am	Keynote address - Updates and emerging indications for thoracic SABR Professor Clifford G. Robinson, Professor of Radiation Oncology Chief, Stereotactic Body Radiation Therapy (SBRT) Associate Director, Clinical Programs, Washington University School of Medicine, St Louis, USA
12.00pm	Sponsored session supported by Elekta Sustainability: The Triple Win of Hypofractionation Elizabeth Knowles, Principal Product Manager, Elekta
12.30pm	SABR QA Programme and trials update Patricia Diez, Lead Clinical Scientist, RTTQA and Dr Rushil Patel, Lead SABR Physicist, RTTQA, Mount Vernon Cancer Centre
1.00pm	Lunch, exhibition and poster viewing
2.10pm	The integration of Artificial Intelligence in the SABR pathway Matthew Clarke, Consultant Clinical Scientist, Radiotherapy Physics Group Leader, The Christie NHS Foundation Trust
2.40pm	Proffered papers in the spotlight Acute Toxicity in the DESTINATION 1 Trial: A Prospective Prostate SBRT Dose De-escalation Feasibility Study, Dr Sian Cooper, Clinical Research Fellow, The Royal Marsden NHS Foundation Trust Urethral sparing and tumour tracking to deliver 3 fraction prostate SBRT: The UK PRECISION Study, Professor Duncan B McLaren, Consultant Clinical Oncologist, Edinburgh Cancer Centre Prostate SABR in Minutes from Set-Up Verification to Beam-Off: Efficient Delivery with FFF Arcs, Michael Roche, Cork University Hospital, Ireland Does an MR-only pathway impact dosimetric and acute clinical outcomes in prostate SABR? Dr Jonathan Wyatt, Lead Clinical Scientist, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust Stereotactic ablative body radiotherapy (SABR) for Bone Metastases in Oligometastatic cancer: Retrospective Analysis from a Tertiary Centre, Dr Sneha Abraham, Specialty Registrar (ST5) - Clinical Oncology, University Hospitals Birmingham NHS Trust
3.30pm	Refreshments, exhibition and poster viewing
4.00pm	The Great British SABR MDT Expert panel: Professor Clifford G. Robinson, Dr Stephen J Harrow, Consultant Clinical Oncologist Thoracic Malignancies & OMD, Edinburgh Cancer Centre, Dr Aidan Cole, Consultant Clinical Oncologist, Belfast Health and Social Care Trust, Marina Khan, Research & Development Lead Radiographer, Guys and St Thomas’ NHS Foundation Trust & Joe Flaherty Clinical Technologist – Treatment Planning Team Lead, University Hospitals Bristol and Weston NHS Foundation With case presentations from: Dr Amanda Swan, Clinical Oncology Registrar, Edinburgh Cancer Centre, Dr David Quigley, SPR, St. James’s Hospital, Belfast Health & Social Care Trust and Dr Clair Brunner, Radiotherapy Research Fellow, Swansea Bay University Health Board
5.00pm	RTT-Led Initiatives in Adaptive Radiation Therapy Winnie Li, Radiation Therapy Manager, Professional Practice and Assistant Professor, Department of Radiation Oncology, University of Toronto, Canada
5.30pm	Closing remarks
7.30pm	UK SABR Consortium Annual Conference Dinner Hilton Hotel, Newcastle, Gateshead
	Friday 21 November - Day two
8.30am	Registration, welcome refreshments, exhibition and poster viewing
8.55am	Chair's introduction Dr Rebecca Muirhead, Consultant Clinical Oncologist, Oxford University NHS Foundation Trust & Vice-Chair, UK SABR Consortium
9.00am	FLAME Trial - boosting prostate patients Professor Uulke Van der Heide, Group leader, Professor at Leiden UMC, Netherlands
9.30am	Expanding indications for SBRT in the management of prostate cancer Post-prostatectomy SBRT: Current evidence and emerging perspectives - Dr Federica Ferrario, Radiation Oncologist, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy The STAMPEDE2 Stereotactic Ablative Body Radiotherapy (SABR) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer (PC) Starting Androgen Deprivation Therapy (ADT) - Dr Hoda Abdel-Aty, Post-CCT Clinical Oncology Specialist Registrar, The Royal Marsden Hospital & STAMPEDE2 trial Senior Research Fellow at The MRC Clinical Trials Unit, UCL STAR-TRAP - Dr Alison Tree, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust Q&A Panel discussion with all speakers
10.30am	Hybrid radiotherapy for stage III lung cancer Professor Gerry Hanna, Trinity College Dublin, Consultant in Radiation Oncology, St Luke's Radiation Oncology Network, Ireland
11.00am	Refreshments, exhibition and poster viewing
11.30am	Dose accumulation in the context of reirradiation Eliana Vasquez Osorio, Senior Research Fellow, The University of Manchester
12.00pm	Sponsored session supported by Accuray Speaker tba
12.30pm	Proffered papers in the spotlight Dose escalation with MR-linac stereotactic boost radiotherapy for brachytherapy ineligible gynaecological cancers: results of the MARGARITA protocol, Kayleigh Brook, Radiotherapy Physicist, The Royal Marsden NHS Foundation Trust 34Gy Single Fraction vs 54Gy in 3 Fraction Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: A Two-Centre Experience and Propensity Matched Analysis, Crispin Hiley, Associate Professor, University College London External validation of a hierarchical Bayesian eGFR predictive model for kidney cancer treated with SABR, Antony Carver, Principal Clinical Scientist, University Hospitals Birmingham NHS Foundation Trust Ultra-hypofractionated radiotherapy to the stellate ganglia for ventricular arrhythmia using MR-guided radiotherapy – pre-trial commissioning, Dr Ben George, Principal Physicist for MR-Linac Service Development, GenesisCare A service evaluation of prostate swelling in ultra-hypofractionated radiotherapy: Assessing changes following a consecutive daily treatment schedule, Daisy Morris, Therapeutic Radiographer, The Clatterbridge Cancer Centre NHS Foundation Trust
1.20pm	Lunch, final exhibition and poster viewing
2.20pm	Considerations for treating oligometastases in colorectal cancer Professor Nicos Fotiadis, Consultant Interventional Radiologist, The Royal Marsden NHS Foundation Trust, Dr Katharine Aitken, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust & Dr Rebecca Muirhead
3.00pm	UK SABR Consortium's Dragon's Den Chairs: Patricia Diez & Dr Aidan Cole Expert Panel: Professor Gerry Hanna, Professor Emma Hall, Professor in Oncology Clinical Trials, The Institute of Cancer Research, Cynthia Eccles, Consultant Research Radiographer, The Christie NHS Foundation Trust, Dr Alison Tree & Professor Clifford G. Robinson Study to evaluate safety and efficacy of single fraction spine stereotactic body ablative radiotherapy (SBRT) with dose de-escalation, Dr. Milan Anjanappa, Mount Vernon Cancer Centre STOP-R: A Randomised Phase II Trial of SABR for Oligoprogression in Metastatic Renal Cell Carcinoma, Dr Rachel Pearson, Consultant Clinical Oncologist, Northern Centre For Cancer Care, Newcastle Upon Tyne Hospitals NHS Foundation Trust A phase Ib/II safety, feasibility and efficacy study of Stereotactic ABlativeRadiotherapy (SABR) with CarbOgen and Nicotinamide (CON) in the treatment ofpatients with oligo-metastatic cancer, Dr Hannah Tharmalingam, Consultant Clinical Oncologist, Mount Vernon Cancer Centre
4.00pm	Closing remarks